Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates

In the 2010s, immunotherapy revolutionized the treatment landscape of multiple myeloma. CD38-targeting antibodies were initially applied as monotherapy in end-stage patients, but are now also approved by EMA/FDA in combination with standards-of-care in newly diagnosed disease or in patients with ear...

Full description

Bibliographic Details

Published in:	Hemato
Main Authors:	Christie P. M. Verkleij, Wassilis S. C. Bruins, Sonja Zweegman, Niels W. C. J. van de Donk
Format:	Article
Language:	English
Published:	MDPI AG 2021-03-01
Subjects:	multiple myeloma immunotherapy antibodies monoclonal bispecific immunoconjugates
Online Access:	https://www.mdpi.com/2673-6357/2/1/7